Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

This Penny Stock (NASDAQ:DYAI) Rose 5% Today: What's Behind the Move

Dyadic International (NASDAQ:DYAI), a penny stock trading around $1 a share, closed up 5.21% on August 6 at $1.02. Dyadic International is a Jupiter, Florida based biotechnology platform company founded in 1979 that leverages its proprietary C1 and Dapibus microbial gene expression platforms, built …

Nitish Kishor | 06 August 2026

Encompass Health (NYSE:EHC) Stock Surges 13% on Strong Q2 Results

Encompass Health (NYSE:EHC) shares closed up 12.55% on August 6 at $124.82 after the inpatient rehabilitation hospital operator posted a strong Q2 2026 report. Encompass Health is the nation's largest owner and operator of inpatient rehabilitation hospitals as measured by patients treated, revenues, and …

Nitish Kishor | 06 August 2026

Evotec (NASDAQ:EVO) and Odyssey Therapeutics (NASDAQ:ODTX) Enter AI-Enabled R&D Collaboration to Target Autoimmune and Inflammatory Diseases

Evotec (NASDAQ:EVO) announced a strategic research and development collaboration with Odyssey Therapeutics (NASDAQ:ODTX) aimed at discovering new treatments for autoimmune and inflammatory diseases. Under the agreement, Odyssey will draw on Evotec's integrated, data-driven discovery platform, along with its advanced screening capabilities and AI-enabled data …

Nitish Kishor | 06 August 2026

Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) Both Beat Q2 Estimates and Raise Guidance, but Investors React in Opposite Directions

Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both delivered second-quarter results that exceeded Wall Street's expectations and prompted both companies to raise their full-year outlooks, yet the market's reaction could not have been more different. Lilly shares rose on the day of its report, …

Nitish Kishor | 06 August 2026

Amazon (NASDAQ:AMZN) Pharmacy to Offer Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) Weight-Loss Drugs for $50 a Month Under Medicare Bridge Program

Amazon's (NASDAQ:AMZN) pharmacy unit said it will offer weight-loss drugs to eligible Medicare beneficiaries for $50 a month through the Medicare GLP-1 Bridge Program, a federal initiative created to expand access to the treatments. The program, which launched last month and runs through the …

Nitish Kishor | 06 August 2026

Zai Lab Posts $106.3M Revenue in Q2 2026, Misses Estimates

Zai Lab Limited reported total revenues of $106.3 million for the second quarter of 2026, falling short of the $110.0 million seen the previous year and below market expectations. This disappointing performance highlights challenges faced in stabilizing product demand, despite year-over-year product revenue increasing …

Vinay Lochav | 06 August 2026

Zoetis Inc. (NYSE: ZTS) Posts $1.87 EPS, Shares Down 40.9% Year-to-Date

Zoetis Inc. (NYSE: ZTS) released its second-quarter results, revealing no growth in revenue, which totalled $2.5 billion, flat compared to the same period last year. The company's adjusted net income increased slightly by 1% to $781 million, reflecting stronger performance on a diluted share …

Vinay Lochav | 06 August 2026

Teleflex (NYSE: TFX) Posts Q2 Adjusted EPS of $1.76, Beating Estimates by 36%

Teleflex Incorporated (NYSE: TFX) delivered a strong second quarter performance, announcing adjusted earnings per share of $1.76, a substantial improvement over the consensus estimate of $1.29. The company saw its revenue from continuing operations reach $570.3 million, marking a strong 28.9% increase year-over-year. The …

Vinay Lochav | 06 August 2026

Viatris (NASDAQ: VTRS) Reports 5% Revenue Growth to $3.8 Billion in Q2 2026

Viatris Inc. reported total revenues of $3.8 billion for the second quarter ended June 30, 2026, marking a solid 5% increase from the previous year. The results surpassed market expectations, with earnings per share at $0.69 compared to a consensus estimate of $0.61. Driven …

Vinay Lochav | 06 August 2026

Viridian Therapeutics (NASDAQ: VRDN) Sees 11.6% Share Surge Following Earnings Results

Viridian Therapeutics, Inc. achieved an earnings per share (EPS) of $-0.90 for the second quarter of 2026, surpassing the consensus estimate of $-1.12. This marked improvement highlights the company's ongoing efforts to manage costs and optimize operations in its biotechnology focus on autoimmune diseases. …

Vinay Lochav | 06 August 2026
Support

Hi! How can we help you today?

Loading…